The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers convenient weekly dosing compared with daily basal insulin injections.
Continue reading at WebMD.
Awiqli: Fda Approves First And Only Once-Weekly Long-Acting Basal I…
